Intravitreal anti-VEGF therapy as a treatment for retinopathy of prematurity: what we know after 7 years.

Abstract

The authors review published clinical case reports, case series, and clinical trials evaluating the use of anti-vascular endothelial growth factor (VEGF) medications for the primary or adjunctive treatment of retinopathy of prematurity (ROP). A literature search of peer reviewed reports on PubMed was performed. More than 50 pertinent peer-reviewed publications between 2006 and 2014 were selected to be included in this review and are summarized in this report. There is a growing body of literature on the use of anti-VEGF therapy as a treatment for ROP, predominately in the form of case reports and small case series. Adverse effects from anti-VEGF treatment for ROP have been reported, but with limited follow-up time. The use of anti-VEGF as a treatment for ROP remains off-label.

DOI: 10.3928/01913913-20150216-01
020406020162017
Citations per Year

Citation Velocity: 10

Averaging 10 citations per year over the last 2 years.

Learn more about how we calculate this metric in our FAQ.

Cite this paper

@article{Klufas2015IntravitrealAT, title={Intravitreal anti-VEGF therapy as a treatment for retinopathy of prematurity: what we know after 7 years.}, author={Michael A. Klufas and R. V. P. Chan}, journal={Journal of pediatric ophthalmology and strabismus}, year={2015}, volume={52 2}, pages={77-84} }